Weigh to Wellness Denver

07/31/2026

Dr. Andrick joined her friend and colleague Dr. Carolynn Francavilla as guests on the Weight and Measure podcast talking about comprehensive obesity care and what that looks like for patients to be sure you get the care you deserve. Thank you to the hosts of this episode Zach and Deb!

Podcast Episode · Weight & Measure · July 20 · 1h 23m

07/11/2026

Colorado Health First (Medicaid) is adopting the new federal legislation on work requirements. It is confusing but crucial people understand the new rules to keep their coverage. Here is a link to a good explainer!

https://www.medicaid.gov/renew-info/CO?utm_source=fb&utm_medium=paid_social&utm_campaign=2026-ce&utm_content=gen&dclid=CKSe9IPZypUDFRWDAAAdsBYUUw&gad_source=7&fbclid=IwVERFWAS_H9JwZG9mA2ZkaWQWUKVe0EW2FauyeusWhMhhOQZJ7mjddGV4dG4DYWVtATAAYWRpZAGrNu9u0MhLc3J0YwZhcHBfaWQPMTczODQ3NjQyNjcwMzcwAAEezgAGzpbvEy794LUeqblIsXMi8lvJy93miSPf6QgAE2De2fIauUHcK3o7fvM_aem_bNjfCeifnZqdiwJY06WMWA

Medicaid eligibility rules are changing. You may need to meet a new monthly work requirement to qualify for Medicaid and keep your coverage. Some states have already started the new requirement and others will start soon.

06/27/2026

Great webinar by Colorado based obesity specialist, friend and colleague, John Michael Taormina, MD speaking about what long-term obesity care looks like. Give it a listen! Here is the YouTube link.

What does long-term obesity treatment actually look like? In this e...

05/06/2026

Dr Andrick talks with friend and colleague Dr Carolynn Francavilla on her podcast “The Dr Francavilla Show” about the new oral GLP1 agonist Foundayo for treating the chronic disease of obesity. Give it a listen!

What If You Could Get the Benefits of a GLP-1 — Without the Needle? That's exactly the question Foundayo is answering — and it's one that a lot of patients have been waiting to ask. For years, one of the biggest barriers to GLP-1 therapy has been the injections. Not everyone is comfortable with ...

03/14/2026

Interested in longevity and longer healthspan? Prevention of cardiovascular disease is key! New joint guidelines on the management of high cholesterol/high triglycerides (dyslipidemia) for decreasing risk of cardiovascular/heart disease from the American College of Cardiology, American Heart Association and others (listed below). They recommend earlier and repeat screening (including genetic risk of early CVD with Lp(a))calculating CVD risk assessing factors like family history, hypertension etc and earlier treatment initiation for optimal prevention. # Healthy❤️

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

1.Treat dyslipidemia earlier to reduce lifetime exposure to atherogenic lipoproteins; start lifestyle counseling in youth and consider early pharmacotherapy in high-risk individuals (e.g., familial hypercholesterolemia or LDL-C ≥160 mg/dL).
2.Use the PREVENT™ risk equations instead of older models to estimate 10- and 30-year ASCVD risk in adults aged 30–79, applying the CPR approach: Calculate risk, Personalize assessment, and Reclassify if needed (e.g., with CAC).
3.Consider LDL-lowering therapy in primary prevention starting at a 10-year risk of 3–5%, and recommend it more strongly at 5–10%, after clinician–patient discussion.
4.LDL-C and non-HDL-C targets are reintroduced, while maintaining focus on percentage LDL reduction based on ASCVD risk.
5.Apolipoprotein B (ApoB) measurement can help detect residual lipoprotein-related risk, especially in patients with high triglycerides, diabetes, or low LDL-C.
6.Measure Lipoprotein(a) at least once; elevated levels significantly increase ASCVD risk and warrant more intensive LDL-lowering strategies.
7.Coronary artery calcium (CAC) scoring can refine risk assessment and treatment decisions, particularly in men ≥40 and women ≥45 years.
8.LDL-lowering therapy is recommended for adults aged 40–75 with diabetes, CKD stage 3–4, or HIV regardless of LDL-C level.
9.In secondary prevention, stricter targets are recommended: LDL-C

03/12/2026

Wishing a happy RDN day to our fabulous dietitians, Sam and Liz! Thank you for all you do to educate people on nutrition for a healthier lifestyle and support them on the journey!

🎈 Happy Registered Dietitian Nutritionist Day! 🎈

🎉 Today and every day, we recognize and thank all the RDNs out there for your commitment to improving the health of your patients, clients and communities. 🙏

🔗 More on and all the ways to celebrate: sm.eatright.org/RDNday

03/03/2026

Obesity is a chronic disease and evidence based, effective treatments can really help halt the progression, improve co-occurring conditions and prevent weight recurrence with long term management. Weight bias and stigma are blocking insurance coverage for comprehensive obesity care and all of us advocating for access to treatment is what will change this. For easy ways to do this check out the OAC website!
www.obesityaction.org

02/12/2026

I talk about metabolic adaptation after weight loss and why it makes keeping weight off long term is so difficult with my patients daily Obesity expert Dr Kushner with a great explanation for medical providers but valuable information for everyone trying to manage their weight.

Metabolic adaptation hinders the ability for persons with obesity to maintain weight loss. But long-term incretin-based therapy combined with lifestyle intervention can support durable weight loss.

11/14/2025

What is the difference between motivation and discipline, and what should we rely on to follow through with our goals? Read this month's blog post for more guidance on ways to support and maintain healthy habits.

11/14/2025

What can we expect from last week’s announcement about increased access to anti-obesity medications for Medicare recipients? Below is an explainer of the details from Joe Nadglowski, the fearless leader of the OAC.
I encourage you to follow them on Facebook, always great information and education on obesity.

Last week brought major movement in obesity care. While the OAC team was connecting with partners and advocates at ObesityWeek, historic news broke from Washington — Medicare is set to cover obesity medications starting in 2026. In our latest blog, OAC CEO Joe Nadglowski reflects on this incredible week, what it means for the future of access to care and the work that still lies ahead. Read the full blog here: https://bit.ly/3JSoLOH